Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sameer Parekh

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Vaccine|September 20, 2024
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlersHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Frontiers in Immunology|July 16, 2025
Quantitative bead-based multiplex assay for simultaneous determination of IgG concentrations of pertussis toxin, filamentous hemagglutinin, pertactin, diphtheria, tetanus, Haemophilus influenzae b, and hepatitis B in human serum samplesVishal Rathod, Sagar Katke, Sumant Patil, et al.
Expert Review of Vaccines|March 8, 2023
Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in IndiaHitt J Sharma, Sameer Parekh, Pramod Pujari, et al.
The Lancet. Oncology|November 10, 2023
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trialHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
NPJ Vaccines|February 21, 2024
A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL<sup>®</sup>) in infantsHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Vaccine|September 20, 2024
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlersHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Frontiers in Immunology|July 16, 2025
Quantitative bead-based multiplex assay for simultaneous determination of IgG concentrations of pertussis toxin, filamentous hemagglutinin, pertactin, diphtheria, tetanus, Haemophilus influenzae b, and hepatitis B in human serum samplesVishal Rathod, Sagar Katke, Sumant Patil, et al.
Expert Review of Vaccines|March 8, 2023
Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in IndiaHitt J Sharma, Sameer Parekh, Pramod Pujari, et al.
The Lancet. Oncology|November 10, 2023
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trialHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
NPJ Vaccines|February 21, 2024
A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL<sup>®</sup>) in infantsHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Pageof 3